Katkin Keith
SEC Form 4 insider trading activity
Katkin Keith has filed 3 SEC Form 4 filings (4 transaction rows) across 3 companies, including EBS, SNDX, ELDN, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: May 4, 2026.
On the most recent filing, Katkin Keith is listed as Director at Emergent BioSolutions Inc. Inside the rolling window, Katkin Keith reported no open-market purchases and 1 open-market sale totaling $128K in EBS.
Companies traded
Other insiders at EBS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$128K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Katkin Keith made?
Katkin Keith has filed 3 SEC Form 4 filings (4 transaction rows) across 3 companies, including EBS, SNDX, ELDN since 2026.
Which companies does Katkin Keith trade?
Katkin Keith has filed SEC Form 4 disclosures for 3 companies, including EBS, SNDX, ELDN.
When was Katkin Keith's most recent SEC Form 4 filing?
Katkin Keith's most recent SEC Form 4 filing on Tracefour is dated May 4, 2026.
What is Katkin Keith's total buy and sell value in the current window?
Inside the rolling retention window, Katkin Keith bought $0 and sold $128K based on SEC Form 4 filings.
What was Katkin Keith's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 15,481 EBS shares on 2026-04-30, worth $128K, per SEC Form 4 filings.